Mutual of America Capital Management LLC Has $3.98 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)

Mutual of America Capital Management LLC boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,673 shares of the medical research company’s stock after acquiring an additional 241 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Bio-Rad Laboratories were worth $3,979,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chicago Equity Partners LLC raised its position in Bio-Rad Laboratories by 108.9% during the fourth quarter. Chicago Equity Partners LLC now owns 3,875 shares of the medical research company’s stock worth $925,000 after acquiring an additional 2,020 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at about $1,901,000. SG Americas Securities LLC raised its position in shares of Bio-Rad Laboratories by 1,226.6% in the fourth quarter. SG Americas Securities LLC now owns 9,883 shares of the medical research company’s stock valued at $2,359,000 after purchasing an additional 9,138 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at about $329,000. Finally, State of Alaska Department of Revenue raised its position in shares of Bio-Rad Laboratories by 57.7% in the fourth quarter. State of Alaska Department of Revenue now owns 3,800 shares of the medical research company’s stock valued at $906,000 after purchasing an additional 1,390 shares during the period. 63.72% of the stock is currently owned by hedge funds and other institutional investors.

In related news, VP James R. Stark sold 746 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $270.51, for a total transaction of $201,800.46. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Christine A. Tsingos sold 4,980 shares of the firm’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $249.40, for a total transaction of $1,242,012.00. Following the transaction, the chief financial officer now directly owns 7,283 shares in the company, valued at $1,816,380.20. The disclosure for this sale can be found here. Insiders sold 9,126 shares of company stock worth $2,309,426 over the last three months. Insiders own 28.29% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Wells Fargo & Co reissued an “outperform” rating and issued a $290.00 price objective (up from $250.00) on shares of Bio-Rad Laboratories in a research report on Wednesday, November 29th. TheStreet raised shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research report on Monday, November 13th. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $291.00 price objective on the stock in a research report on Wednesday, December 13th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Bio-Rad Laboratories presently has a consensus rating of “Buy” and a consensus target price of $277.75.

Bio-Rad Laboratories, Inc. (BIO) opened at $243.76 on Thursday. The firm has a market cap of $7,335.69, a PE ratio of 78.24, a PEG ratio of 1.94 and a beta of 0.97. Bio-Rad Laboratories, Inc. has a 1 year low of $186.98 and a 1 year high of $273.87. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77.

Bio-Rad Laboratories declared that its board has approved a share repurchase program on Tuesday, November 28th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/02/08/mutual-of-america-capital-management-llc-has-3-98-million-holdings-in-bio-rad-laboratories-inc-bio.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply